Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility
Novo Nordisk has terminated two additional phase 3 trials of its cardiovascular drug ziltivekimab due to futility, impacting its growth strategy.
🌍 Cross-language spread
This story first appeared in 🇩🇪 German coverage — 4.1 hours before PULSE detected it in English news.
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Novo Nordisk stopped two cardiovascular trials of its IL-6 heart drug ziltivekimab early for futility. Consequently, the company's blockbuster hopes and growth prospects for the chronic kidney disease program and cardiovascular studies dwindled.
Epilogue added 58d ago, after coverage quieted.
The brief
Novo Nordisk has announced the termination of two cardiovascular trials involving ziltivekimab, a drug designed to lower inflammation by targeting IL-6. According to reports from Endpoints News and STAT, these specific studies were stopped early because of futility. This decision comes as part of a broader trend of trial cancellations for the pharmaceutical company, specifically affecting its efforts to expand its therapeutic reach into heart failure and chronic kidney disease. The move indicates that the drug failed to meet the necessary benchmarks to justify the continuation of these particular clinical assessments. Coverage from Reuters and Fierce Biotech emphasizes that these cancellations significantly diminish the company's hopes for its chronic kidney disease program. Reuters specifically highlights that these failed trials dim the prospects for Novo Nordisk's growth beyond its current success in the obesity market.
Firstwordpharma.com further notes that the company's aspirations for ziltivekimab are dwindling as the heart failure studies were stopped prematurely. These outlets collectively frame the event as a setback for a company seeking to diversify its blockbuster portfolio away from weight-loss medications. To understand why this matters, it is necessary to recognize the strategic importance of the IL-6 heart drug in Novo Nordisk's long-term pipeline. The company had positioned ziltivekimab as a potential driver of future revenue, aiming to tackle inflammatory markers associated with heart disease and kidney dysfunction. By attempting to move into the cardiovascular space, the company sought to replicate the commercial success of its obesity treatments. The failure of these phase 3 trials suggests a significant hurdle in the drug's ability to provide the clinical benefit required for regulatory approval and market entry.
Moving forward, the industry will be watching for further updates on the remaining components of Novo Nordisk's CKD and cardiovascular programs. Based on the reporting from Endpoints News and other outlets, the primary focus remains on whether any other trials for ziltivekimab will be maintained or if the entire program will be reconsidered. There is a stated need for the company to find new avenues for growth to sustain its trajectory outside of the obesity sector. Future disclosures will likely clarify the total number of scrapped trials and the resulting impact on the company's overall research and development pipeline.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 70d ago.
Quick answers
Which drug was involved in the cancelled trials?
The drug is ziltivekimab, which targets IL-6 to lower inflammation.
Why were the trials stopped?
The trials were stopped early due to futility.
Which therapeutic areas were affected by these cancellations?
The cancellations affected heart failure studies and the company's chronic kidney disease (CKD) program.
Coverage (5)
- Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped Fierce Biotech · 72d ago
- Novo's hopes for ziltivekimab dwindle as two heart failure studies stopped early firstwordpharma.com · 72d ago
- Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation STAT · 72d ago
- Novo scraps two more heart drug trials, further dimming growth beyond obesity Reuters · 72d ago
- Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futility Endpoints News · 72d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
WHO Releases First Guidelines On Type 1 Diabetes In Adults: What To Know
WHO publishes its first-ever clinical guidelines for type 1 diabetes in adults, urging cheaper insulin access and multiple daily injections.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.
Experts spell out what heart health means for women of all ages
New joint heart health guidance from the American Heart Association and three other medical groups urges cardiovascular screening for women at every life stage.
Column | Your stroke risk is 72 percent higher during these 3 hours of the day
Multiple outlets report stroke risk spikes 72 percent higher during a specific three-hour morning window, citing new medical research.
FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.